BioZone Scientific Technology Independently Confirmed to Be Effective Against SARS-CoV-2, the Virus That Causes COVID-19

December 10, 2020

BioZone Scientific Technology residential, commercial, and healthcare products were independently tested for effectiveness against SARS-CoV-2 by a third-party lab.

In the test report titled, “SARS-CoV-2 Surrogate Inactivation by Ultraviolet Disinfection System from BioZone Scientific,” the systems repeatedly delivered greater than 5-log inactivation (>99.999%) of the SARS-CoV-2 virus in less than one second of exposure to BioZone Scientific ultraviolet disinfection systems.

The testing was conducted by BioZone Scientific Technology Laboratories, an ISO/IEC 17025 certified Florida, USA-based lab which is also accredited by the US Centers for Disease Control, US Environmental Protection Agency, US Department of Agriculture, and Florida Department of Health. The test was designed to model exposure time comparative to inactivating the SARS-CoV-2 virus in the moving airstream within HVAC systems.

A leading manufacturer in HVAC UV light solutions for the disinfection of air and surfaces, BioZone ​Scientific technology has been used by thousands of people around the world for safe disinfection of homes, restrooms, transport, and businesses.

This study joins others, including those published in the Journal of Clinical Virology, that demonstrate that BioZone ​Scientific’s advanced ultraviolet disinfection systems are effective at inactivating viruses and other infectious diseases.

Paul Morris, BioZone ​Scientific’s Senior Vice President for Global Business Development, stated, “This is more welcome evidence that BioZone ​Scientific’s long experience of delivering innovative and effective Biological Defense systems for our clients is based on several critical philosophies – innovation, responsiveness to our clients’ needs, and sound, certified, scientific data. These accredited test results are the latest in a long line of groundbreaking and independently verified test programs that have been undertaken by BioZone Scientific, including research on the effectiveness of our technology against viruses by the French Centre for National Virology Research and papers published in the Journal of Clinical Virology.

This long term and consistent approach gives BioZone ​Scientific’s partners the confidence that they are working with technology that is always ahead of the field in terms of reliability, quality, and effectiveness. We believe this approach is at the center of our success, and the success of our clients.”

Ari Ahola, CEO of BioZone Scientific, stated, “These third-party test results show that BioZone Scientific systems are essential in delivering virus-free environments and are critical components of return to work protocols. In less than a second, BioZone solutions are capable of disinfection rates almost below the levels of detection. We’re immensely proud of these findings, which are well in line with other scientific tests of BioZone ​Scientific technologies. Our mission is to limit the spread of COVID-19 and help people to return to work safely.”

BioZone Scientific Technology is the leader in ultraviolet disinfection systems and has been at the forefront of UV technology for decades. It has a proven track record of innovation in disinfection technologies, which are designed, manufactured, and installed in line with the highest safety standards.

Visit BioZone ​Scientific Technology COVID-19 validation testing.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version